Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive Multiple Sclerosis patients
NUI Galway are looking for people to take part in a new programme
Causes, attributions and intervention needs
Queens researchers in £2 million bid to reverse the damage of Multiple Sclerosis
Survey is now closed
Make your voice heard!
Research showcase and 9,000 steps for MS walk
Memory, attention and concentration